Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
By contrast, a recent clinical trial by Eli Lilly tracked nearly 400 subjects who switched from shots to Foundayo, and found that on average, they maintained most of their weight loss after 52 weeks
This breaks down how long a typical AHK-Cu cycle runs and what research suggests happens at each stage
Peptide Therapy Adults Over 60: Who Is and Is Not a Candidate Strong Candidates Adults 60+ with documented low IGF-1 on serum testing Individuals with sarcopenia confirmed by DEXA or functional testing Active seniors experiencing delayed recovery, poor sleep, and reduced energy not explained by other pathology Adults managing visceral obesity with inadequate response to diet and exercise Individuals already on andropause or menopause hormone therapy who want adjunctive metabolic support Poor Candidates or Contraindicated Any history of active cancer (especially hormone-sensitive: prostate, breast, colon) Uncontrolled diabetes (HbA1c above 8.5%) Severe cardiac or renal impairment Active intracranial pathology (GH secretagogues stimulate pituitary
thereafter the trajectory plateaued
